Sanara MedTech swings to Q3 2026 net loss from continuing operations of $1.29 million year over year
SMTI•Sanara MedTech reported a $1.3 million third-quarter loss from continuing operations, while revenue rose 8% year over year to $28.4 million. It lowered 2026 revenue guidance to $110 million-$115 million from $116 million-$121 million.
1. Quarterly results and guidance
Sanara MedTech swung to a third-quarter 2026 loss from continuing operations of $1.3 million, partly due to merger-related costs. Revenue increased 8% year over year to $28.4 million, driven by higher soft tissue repair product sales. The company lowered its full-year 2026 revenue guidance to $110 million-$115 million from $116 million-$121 million. Shareholders approved MiMedx's pending acquisition in September, and regulatory review remains underway.
